ClinicalTrials.gg
Enrolling by invitationNCT07542262NIVO402025Updated Apr 24, 2026

Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers

A Phase 2 interventional study of Low-dose nivolumab and Low-dose nivolumab with/without chemotherapy in Colorectal Cancer and Gastric Cancer, sponsored by Blokhin's Russian Cancer Research Center. Enrolling by invitation at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Blokhin's Russian Cancer Research Center · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jun 2025, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 38 studies testing nivolumab in Colorectal Neoplasms — 7 open to participants now, 13 under way, 1 of them phase 3. Nivolumab · Colorectal Neoplasms.

Planned enrollment
10th of 38
128 · median 49
Started
2025
with 1 other
Phase 2
23 of 38
7 open now
Primary completion
2028-03
later than 10 of 12 live
Registered
37th of 38
by date
Lead sponsor
2 of 38
Blokhin's Russian Cancer Research Center

Among the 38 studies testing nivolumab in Colorectal Neoplasms, this one is the 10th largest by planned enrollment, is one of 2 that started in 2025, is one of 23 in phase 2, reaches primary completion later than 10 of the 12 other live ones, and was the 37th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 38 studies testing nivolumab in Colorectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing nivolumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

It is planned to study the effectiveness of low-dose immunotherapy (IT) nivolumab 40 mg for either 2 courses of therapy or 6 courses as preoperative therapy in patients with dMMR/MSI locally advanced CRC. Parallel recruitment into subgroups of patients by randomization is assumed.

For dMMR/MSI locally advanced gastric cancer, it is planned to study the effectiveness of low-dose immunotherapy nivolumab 40 mg with or without the addition of chemotherapy (CT) in the FOLFOX regimen as preoperative therapy.

Subgroup A includes 6 cycles of IV CT FOLFOX + IV administration of nivolumab 40 mg once every 14 days, subgroup B - 2 cycles of intravenous administration of nivolumab at a dose of 40 mg once every 14 days, and subgroup C - 6 cycles of intravenous administration of nivolumab at a dose of 40 mg once a day 14 days. Thus, it is planned to gradually include patients in the treatment subgroups.

The frequency of complete therapeutic tumor pathomorphoses (pCR, TRG1) will be evaluated as the primary endpoint. Secondary goals are to study the safety of drug doses, to assess the frequency of pronounced therapeutic tumor pathomorphoses (MPR, TRG 1-2), to assess disease-free survival (PFS), the frequency of R0 resections, overall survival(S), and the frequency of objective response.

To study the use of low-dose immunotherapy in combination with chemotherapy in patients with metastatic dMMR/MSI CRC and gastric cancer in the first line of therapy, it is planned to use a combination of nivolumab 40 mg with FOLFOX regimen once every 14 days for 8 treatment cycles, followed by a switch to supportive intravenous monotherapy with nivolumab 40 mg.

Read the detailed description

It is planned to study the effectiveness of low-dose immunotherapy (IT) nivolumab 40 mg for either 2 courses of therapy or 6 courses as preoperative therapy in patients with dMMR/MSI locally advanced CRC. Parallel recruitment into subgroups of patients by randomization is assumed.

For dMMR/MSI locally advanced gastric cancer, it is planned to study the effectiveness of low-dose immunotherapy nivolumab 40 mg with or without the addition of chemotherapy (CT) in the FOLFOX regimen as preoperative therapy.

Subgroup A includes 6 cycles of IV CT FOLFOX + IV administration of nivolumab 40 mg once every 14 days, subgroup B - 2 cycles of intravenous administration of nivolumab at a dose of 40 mg once every 14 days, and subgroup C - 6 cycles of intravenous administration of nivolumab at a dose of 40 mg once a day 14 days. Thus, it is planned to gradually include patients in the treatment subgroups.

The frequency of complete therapeutic tumor pathomorphoses (pCR, TRG1) will be evaluated as the primary endpoint. Secondary goals are to study the safety of drug doses, to assess the frequency of pronounced therapeutic tumor pathomorphoses (MPR, TRG 1-2), to assess disease-free survival (PFS), the frequency of R0 resections, overall survival(S), and the frequency of objective response.

To study the use of low-dose immunotherapy in combination with chemotherapy in patients with metastatic dMMR/MSI CRC and gastric cancer in the first line of therapy, it is planned to use a combination of nivolumab 40 mg with FOLFOX regimen once every 14 days for 8 treatment cycles, followed by a switch to supportive intravenous monotherapy with nivolumab 40 mg.

One-year AFD will be evaluated as the primary endpoint in the group with metastatic disease. Secondary goals are to study the safety of drug doses, and to evaluate one-year DFS, OS, and CSR.

To develop methods for personalizing low-dose IT, it is planned to compare the number of PD-1-positive cells before treatment and during immunotherapy. It is expected to detect PD-1 blockade on the lymphocyte surface during therapy and assess its duration. The results of the study will be presented in the form of an indicator of the number of PD-1-positive cells (%) and an indicator of the protein density on the surface of positive cells (MFI - average fluorescence intensity).

Peripheral venous blood samples in an anticoagulant tube (3 ml) are planned before the start of therapy, before the second injection of anti-PDL antibodies and, if long-term immunotherapy is received, after 8 weeks. Monoclonal antibodies to CD45, CD4, CD8, CD279 (PD-1), and IgG4 will be used as reagents. The equipment is a BD FACS Canto II flow cytometer.

To analyze the features of radiological evaluation of the effectiveness of checkpoint inhibitor therapy (pseudoprogression), radiological monitoring will be performed before the start of therapy, before surgical treatment, and every 8 weeks of treatment with prolonged immunotherapy. The response to treatment will be evaluated according to the RECIST criteria in revision 1.1.

03

Conditions studied

  • Colorectal Cancer
  • Gastric Cancer

Keywords

  • colorectal cancer
  • gastric cancer
  • low-dose immunotherapy
  • MSI
  • dMMR
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Availability of voluntarily signed from the patient;
  • Men and women, 18 years old \</=;
  • confirmed adenocarcinoma of the colon/rectum/stomach;
  • Presence of MSI/dMMR in the tumor;
  • For M0-cohort: locally advanced tumor - cT3-4N0-2M0 according to CT for tumors of the colon and sigmoid colon; cT3 with a depth of tissue invasion ≥5mm (cT2N0 and higher for lower ampullary cancer) or T4 or involvement of the lateral resection margins according to MRI for rectal cancer; for gastric cancer: cT2\</=, N0-3, no presence of tumour cells in peritoneum (cyt-);
  • For M1-cohort: non-resectable locally-advanced, disease
  • 0-2;
  • No to surgical treatment of

Exclusion criteria

Exclusion Criteria:

  • Previous therapy with the inclusion of monoclonal antibodies - anti-PD1, , anti PD-L2, anti-CTLA4 antibodies and other immunotherapy drugs
  • The presence of any other malignant tumor, with the exception of radically treated basal cell carcinoma, cervical cancer in situ, currently or within 5 years before inclusion in the study
  • Pregnant and lactating women, as well as planning pregnancy during the period of therapy in a clinical trial and 6 months after the end of therapy
  • Patients with preserved who refuse to use adequate methods of throughout the study and 6 months after the end of therapy or who agree to abstain from heterosexual contact.
  • Previous systemic therapy with drugs (including, but not limited to: prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide and TNF [tumor necrosis factor] antagonists) within 4 weeks before signing the form, or the need to use immunosuppressive therapy in during the first year of the study.
  • The use of systemic glucocorticosteroids (GCS) in replacement doses (for example, in a dose equivalent to 10 mg of prednisolone per day or less), short-term use of systemic GCS (≤7 days), inhaled and topical GCS are allowed.
  • Active, known or suspected diseases (patients with type 1 diabetes mellitus and hypothyroidism requiring only hormone replacement therapy, as well as autoimmune diseases with only skin manifestations [for example, vitiligo, alopecia or psoriasis without symptoms of psoriatic arthritis] are allowed to participate), that do not require systemic therapy);
  • Patients with infection, active , active .
  • less than 6 months.
  • The presence of a disease or condition that, in the opinion of the investigator, prevents the patient from participating in the study.
  • Complicated course of the primary tumor, requiring urgent surgical intervention.
  • Previously performed radiation or chemotherapy for colorectal cancer or gastric cancer, with the exception of cases of metachronous tumors over 5 years ago;
  • Persistence, progression or recurrence of the underlying disease or the presence of distant
  • Conditions limiting the patient's ability to comply with the requirements of the protocol (in the opinion of the investigator);
  • Vaccination with within 28 days before randomization;
  • Participation in other interventional clinical trials less than 30 days before randomization (except in cases of dropout before the introduction of study therapy) and while participating in an ongoing clinical trial;
  • Significant adverse events from previous therapy, with the exception of chronic and/or irreversible events that cannot influence the assessment of the safety of the study therapy (for example, alopecia);
  • or allergic reactions to the administration of drugs manufactured using Chinese hamster ovary cells, severe allergic reactions, anaphylaxis or other hypersensitivity reactions to chimeric or humanized antibodies, or any of the components of the study drug.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Cohort 1. dMMR/MSI locally advanced CRC

    Efficacy of low-dose immunotherapy (IT) nivolumab 40 mg for either 2 courses of therapy or 6 courses as preoperative therapy. Parallel recruitment of patients into patient subgroups by randomization.

    Drug: Low-dose nivolumab

  • Experimental
    Cohort 2. dMMR/MSI locally advanced gastric cancer

    Subgroup A includes 6 cycles of IV CT FOLFOX + nivolumab 40 mg once every 14 days; subgroup B - 2 cycles of intravenous administration of nivolumab 40 mg once every 14 days; subgroup C - 6 cycles of of nivolumab 40 mg once a day 14 days. It is planned to gradually include patients in the subgroups.

    Drug: Low-dose nivolumab with/without chemotherapy

  • Experimental
    Cohort 3. Metastatic dMMR/MSI CRC and gastric cancer in the first line

    The use of low-dose immunotherapy in combination with chemotherapy (nivolumab 40 mg + FOLFOX regimen once every 14 days for 8 cycles + maintenance monotherapy nivolumab 40 mg)

    Drug: Low-dose nivolumab combined with chemotherapy

Interventions

  • DrugNivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    nivolumab 40 mg

  • DrugLow-dose nivolumab with/without chemotherapy

    Subgroup A - 6 cycles of IV CT FOLFOX + nivolumab 40 mg once every 14 days; Subgroup B - 2 cycles of IV of nivolumab 40 mg once every 14 days; Subgroup C - 6 cycles of of nivolumab 40 mg once a day 14 days.

  • DrugLow-dose nivolumab combined with chemotherapy

    Drug page: NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Metastatic dMMR/MSI CRC and gastric cancer in the first line - the use of low-dose immunotherapy in combination with chemotherapy (nivolumab 40 mg + FOLFOX regimen once every 14 days for 8 cycles + maintenance monotherapy nivolumab 40 mg)

06

What researchers measure

Primary outcomes

  1. Pathological complete response (pCR) - for M0

    pCR: absence of malignant cells on the specimen of colon/rectal resection in patients who were previously treated with neoadjuvant immunotherapy, TRG1 by Mandard

    Time frame: up to 8 months

  2. One-year progression-free survival (PFS) - for M1

    Time from initiation of treatment to the occurrence of disease progression or death.

    Time frame: 12 months

Secondary outcomes

  1. Major pathologic response (MPR) - for M0

    Rate of pathologic response TRG 1-2

    Time frame: up to 8 months

  2. Progression-free survival (PFS) - for M0

    Time from initiation of treatment to the occurrence of disease progression or death.

    Time frame: 12 months

  3. R0 resection rate - for M0

    Rate of R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed

    Time frame: up to 8 months

  4. Overall survival (OS) - for M0 and M1

    Time from initiation of treatment to death.

    Time frame: 12 months

  5. Objective response rate (ORR) - for M0 and M1

    percentage of patients who achieve a response, which can either be complete response (complete disappearance of lesions) or partial response (reduction in the sum of maximal tumor diameters by at least 30% or more)

    Time frame: up to 8 months

07

Study locations

1 site
  • N.N. Blokhin NMRCO
    Moscow, Russia
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Mar 2028, 33 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 33 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Apr 21, 2026
StartActual
Jun 3, 2025
Primary completionEst.
Mar 30, 2028
CompletionEst.
Mar 31, 2028
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07542262
Lead sponsor
Blokhin's Russian Cancer Research Center
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
Jun 3, 2025
Primary completion
Mar 30, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Apr 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion